ArticleJournal of molecular neuroscience : MN2026
Nicotinic Acetylcholine Receptor of α7 Subtype is Linked to Glioblastoma Cholinergic Heterogeneity.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioblastoma multiforme (GBM) shows tremendous heterogeneity in terms of morphology and gene expression. One of the diagnostically significant characteristics of GBM is the choline peak that can be found in patients’ NMR. Choline derivatives are distributed unevenly throughout the tumor and concentrated, in particular, at the leading edge and infiltrating GBM tumour zones as well as gene transcripts of α7 nicotinic acetylcholine receptor (nAChR), known for its ability to become activated upon choline binding. Since agonist-induced nAChR up-regulation in brain and cell lines has been described and several studies have highlighted the role of nAChR ligands in glioblastoma proliferation in vivo, here we hypothesize for the first time that the complex architecture of glioblastoma might develop partially through choline activation of calcium-permeable α7 nAChR that may contribute to changes in gene expression networks. Using the U87MG glioblastoma cell line, we demonstrated that selective α7 nAChR ligands – agonist (PNU282987) and positive allosteric modulator (PNU120596), and antagonist of α7 and α9 nAChRs (α-cobratoxin, α-CTX, from Naja naja venom) – dynamically regulate nAChR subunit mRNA expression (CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9). α-CTX suppressed agonist-induced CHRNA7 up-regulation in U87MG cells and increased cell viability. Proteomic analysis revealed altered expression of cytoskeletal (ACTG1), metabolic (SHMT2, GLRX3), and endoplasmic reticulum-associated (GANAB) proteins, suggesting the involvement of calcium-dependent signaling downstream of α7 nAChR activation. Quantitative PCR, proteomics and cell viability data were integrated by cellular automata model imitating glioblastoma growth and exposed details of tumour progression, which supports a role for α7 nAChR as one of multiple factors that can help shape intratumoural heterogeneity. These results may have implications for the development of personalized treatment strategies. However, since these findings were obtained in a single cell line, further validation in additional GBM models and in vivo systems is needed before broader conclusions can be drawn.
Indexed as
Identifiers
42012794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.